Last reviewed · How we verify

PTH/Calcium

Shire · Phase 3 active Small molecule

This combination therapy works by supplementing parathyroid hormone (PTH) to regulate calcium homeostasis and bone metabolism.

This combination therapy works by supplementing parathyroid hormone (PTH) to regulate calcium homeostasis and bone metabolism. Used for Hypoparathyroidism, Post-surgical hypoparathyroidism.

At a glance

Generic namePTH/Calcium
Also known asPREOS
SponsorShire
Drug classHormone replacement / Mineral supplement combination
TargetPTH receptor (PTH1R)
ModalitySmall molecule
Therapeutic areaEndocrinology
PhasePhase 3

Mechanism of action

PTH is an endocrine hormone that increases serum calcium levels by stimulating osteoclast-mediated bone resorption, enhancing renal calcium reabsorption, and promoting active vitamin D synthesis. The addition of calcium supplementation supports the PTH mechanism by providing substrate for bone mineralization and maintaining serum calcium levels. Together, these agents address hypocalcemia and related mineral metabolism disorders.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: